Rep. Cleo Fields has bought NVDA three times in recent filings, creating a concentrated bet on the semiconductor leader immediately ahead of its fiscal Q3 2027 earnings. Consensus projections point to EPS near $2.49 and revenue between $108 billion and $109 billion, figures that would reflect roughly 90 percent year-over-year growth and continue the company's streak of beating estimates. Fields' activity stands out within the latest earnings-watch cluster, which logged a total of 15 trades under an N/A designation involving eight lawmakers plus another 18 trades across nine specific tickers.
Ro Khanna appears most frequently in the data, filing one buy and two sells in ORCL ahead of that company's projected early-December report. Analysts expect Oracle to generate EPS of approximately $1.88 on revenue near $21.3 billion, continuing momentum from its recent beat and raised full-year guidance tied to AI cloud infrastructure. Khanna also bought COST twice while splitting trades in MCD and taking sells in both FDX and HD, suggesting he is positioning selectively across consumer defensive, cyclical, and industrial names that report in the coming weeks. Other participants include Rick Larsen on the sell side of FDX and HD, Josh Gottheimer splitting MCD, and Lisa McClain buying IBRX in the healthcare space.
The breadth of names, sectors, and directions reflects a deliberate if varied approach to the earnings calendar. Technology dominates the explicit tickers with NVDA and ORCL, yet consumer cyclicals such as CCL, HD, and MCD plus the defensive COST show lawmakers are not limiting exposure to AI alone. The 7 buys versus 4 sells within the 15-trade N/A group, which lists Scott H. Peters, Gilbert Cisneros, James A. Himes, Kevin Hern, Suzan K. DelBene, Darrell E. Issa, and Rudy Yakym alongside Khanna, adds to the sense of broad portfolio recalibration rather than uniform conviction.
Market sentiment tracked on X underscores why these stocks draw attention. NVDA is projected to contribute heavily to S&P 500 earnings expansion this quarter while Oracle carries a $664 billion backlog that supporters believe will drive revenue doubling over the next two years. Both companies have delivered consistent beats recently, NVDA most recently reporting $96.2 billion revenue in the prior period. Whether the congressional filings prove well-timed will become clear after the releases, yet the overlap between trade dates and these high-stakes catalysts is unmistakable.
This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.